Litigation Details for IN RE: Auryxia (Ferric Citrate) Patent Litigation (J.P.M.L. 2019)
✉ Email this page to a colleague
IN RE: Auryxia (Ferric Citrate) Patent Litigation (J.P.M.L. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-04-18 |
| Court | United States Judicial Panel on Multidistrict Litigation | Date Terminated | 2022-02-10 |
| Cause | Assigned To | Leonard P. Stark | |
| Jury Demand | Referred To | ||
| Patents | 7,767,851; 8,093,423; 8,299,298; 8,338,642; 8,609,896; 8,754,257; 8,754,258; 8,846,976; 8,901,349; 9,050,316; 9,328,133; 9,387,191; 9,757,416 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in IN RE: Auryxia (Ferric Citrate) Patent Litigation
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for IN RE: Auryxia (Ferric Citrate) Patent Litigation (J.P.M.L. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-07-31 | 44 | iii). 4 The patents are U.S. Patent Nos. 7,767,851; 8,093,423; 8,299,298; 8,338,642…MULTIDISTRICT LITIGATION IN RE: AURYXIA (FERRIC CITRATE) PATENT LITIGATION …actions on the motion are a series of Hatch-Waxman3 patent infringement lawsuits, in which Keryx alleges that… Under the Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98–417… “paragraph IV certification”—stating that the patents listed in the FDA’s Orange Book as covering the | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
